{"entity":{"id":"grit-bio","kind":"company","name":"Grit Bio","aka":["Grit Biotechnology","GRIT Biotherapeutics","沙砾生物"],"tldr":"Grit Bio is a China-based cell therapy company that leads 3 cancer trials in OnCo, testing the tumour-infiltrating lymphocyte therapies GT101 and GT201 and the CAR-T GT719 in cervical cancer, non-Hodgkin lymphoma and advanced solid tumours.","summary":"Grit Bio is a late-stage biopharmaceutical company developing next-generation T-cell therapies for cancer and autoimmune disease, with headquarters in Beijing, a research centre in Shanghai and a GMP manufacturing base in Suzhou. Its pipeline includes GT101, an autologous tumour-infiltrating lymphocyte (TIL) therapy in pivotal development, GT201, a TIL therapy expressing membrane-bound IL-15, CAR-T and CAR-iNKT candidates and neoantigen cancer vaccines. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06241781 (phase 2, Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent...), NCT06948981 (phase 1/2, GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Ma...) and NCT06144671 (phase 1/2, Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://grit-bio.com/"},{"label":"ClinicalTrials.gov: trials led by Grit Bio","url":"https://clinicaltrials.gov/search?lead=Grit%20Biotechnology"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cervical","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06241781","nct06948981","nct06144671"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Beijing","country":"CN","companyType":"cell-therapy","website":"https://grit-bio.com/","founded":2019,"stage":"growth","investors":[],"funding":[]},"route":"/companies/grit-bio/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"trial":[{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/"},{"id":"nct06948981","kind":"trial","name":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","route":"/trials/nct06948981/"},{"id":"nct06144671","kind":"trial","name":"Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors","route":"/trials/nct06144671/"}]}}